Clinical Trials

DermatologicGastrointestinalSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00421317 2026-03-13

O-Mel-Inib

Phase 2 Terminated

13 enrolled

Dermatologic

Melanoma

NCT01046487 2026-03-13

PALANGI3

Phase 1 Completed

26 enrolled

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT06124157 2026-03-13

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 3 Recruiting

222 enrolled

Lymphoid

Burkitt Lymphoma

NCT04971226 2026-03-10

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

406 enrolled 18 charts 1 FDA

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04877522 2026-03-06

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

Phase 2 Active not recruiting

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

40 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT03007147 2026-02-23

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

475 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05493215 2026-02-17

Imatinib TDM in GIST

28 enrolled

Gastrointestinal Stromal Tumors

NCT06090669 2026-02-17

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Phase 2 Not yet recruiting

75 enrolled

Classical hematology

Congenital Bone Marrow Failure Syndromes

NCT07406633 2026-02-12

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

46 enrolled

Digestive System Neoplasms, Gastrointestinal Stromal Tumors

NCT05381753 2026-02-11

Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

Completed

61 enrolled

Gastrointestinal Stromal Tumors

NCT06655246 2026-02-05

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

157 enrolled

Phase 4 Active not recruiting

Gastrointestinal Stromal Tumors

NCT01742299 2026-02-02

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

155 enrolled

Gastrointestinal Stromal Tumors

NCT06889168 2026-01-21

LAMP-2

20 enrolled

Lymphangioleiomyomatosis

NCT05152472 2026-01-08

ATEZOGIST

110 enrolled

Neoplasms, Gastrointestinal Stromal Tumors

NCT04626024 2025-12-19

TOKIN

100 enrolled

Phase 2 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

81 enrolled 20 charts

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT02881086 2025-12-16

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Phase 3 Completed

1,023 enrolled

Phase 1/2 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

75 enrolled

Gastrointestinal Stromal Tumors

NCT03578367 2025-11-10

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Phase 2 Completed

104 enrolled 11 charts

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01316250 2025-10-02

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Phase NA Completed

13 enrolled

Phase 1 Not yet recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07171203 2025-09-12

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

18 enrolled

Gastrointestinal Stromal Tumors

NCT04598009 2025-09-03

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

25 enrolled

Dermatologic

Melanoma

NCT05816785 2025-09-03

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

15 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04307576 2025-08-28

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Phase 3 Recruiting

6,430 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00015847 2025-08-22

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase 2 Terminated

25 enrolled 8 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05385549 2025-08-08

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

35 enrolled

Gastrointestinal Stromal Tumors

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

51 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05722795 2025-07-09

I-CONIC

Phase NA Recruiting

40 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03469011 2025-06-27

A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

Phase 1 Terminated

14 enrolled

EndocrineHead & Neck

Thyroid Cancer, Papillary

NCT00476190 2025-06-12

ALL Adult Consortium Trial: Adult ALL Trial

Phase 2 Completed

112 enrolled 17 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

8 enrolled

Phase 3 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT05413915 2025-05-21

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

164 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06962254 2025-05-08

Imatinib and Trametinib for KRAS-mutated Solid Tumor

10 enrolled

Other solid neoplasm

Solid Tumor Cancer

NCT05071482 2025-05-01

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Phase 4 Terminated

39 enrolled

OtherOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01085617 2025-03-30

UKALL14

Completed

Leukemia, Mucositis

NCT03844360 2025-03-30

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Phase 4 Recruiting

1,500 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT05282108 2025-03-26

CARCML

Recruiting

240 enrolled

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT06119789 2025-03-26

MATRIX-Rare